Markus Hartl

Markus Hartl, Ph.D.

Ao. Univ.-Prof. Dr. rer. nat.

Institute of Biochemistry
University of Innsbruck
Room no. L.03.031

Center for Chemistry and Biomedicine (CCB) Innrain 80-82, 6020 Innsbruck / Austria
Phone: +43 512 507 - 57575 | Fax: +43 512 507 - 57599


  1. Hartl M, Willnow T, Fanning, E. cis-active elements from mouse chromosomal DNA suppress simian virus 40 DNA replication.  Virol.64, 2884-2894 (1990).
  2. Kazmierczak B, Bartnitzke S, Hartl M, Bullerdiek J. In vitro transformation by the SV40 'early region' of cells from a human benign salivary gland tumor with a 12q13-q15 rearrangement.  Cell Genet.53, 37-39 (1990).
  3. Hartl M, Hutchins J, Vogt PK. The chicken junD gene and its product. Oncogene6, 1623-1631 (1991).
  4. Vogt PK., Morgan IM., Havarstein L, Su H, Hartl M, Schuur E. The oncogenicity of Jun. Leukemia6 Suppl. 3, s184-s186 (1992).
  5. Hartl M, Vogt PK. Oncogenic transfomation by Jun: Role of transactivation and homodimerization. Cell Growth Differ. 3, 899-908 (1992).
  6. Hartl M, Vogt PK. A rearranged JunD transforms chicken embryo fibroblasts. Cell Growth Differ. 3, 909-918 (1992).
  7. Weiskirchen R, Siemeister G, Hartl M, Bister K. Sequence and expression of a glyceraldehyde-3-phosphate dehydrogenase-encoding gene from quail embryo fibroblasts. Gene128, 269-272 (1993).
  8. Hartl M, Vogt PK, Bister K. A quail long-term cell culture transformed by a chimeric jun oncogene. Virology207, 321-326 (1995).
  9. Hartl M*, Bister K. Specific activation in jun-transformed avian fibroblasts of a gene (bkj) related to the avian beta-keratin gene family.  Natl. Acad. Sci. USA92, 11731-11735 (1995).
  10. Oberst C, Weiskirchen R, Hartl M, Bister K. Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits. Oncogene14, 1109-1116 (1997).
  11. Hartl M*, Bister K. Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation. Oncogene17, 2901-2913 (1998).
  12. Oberst C, Hartl M, Weiskirchen R, Bister K. Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele. Virology253, 193-207 (1999).
  13. Bader AG, Hartl M*, Bister K. Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele. Virology270, 98-110 (2000).
  14. Bader AG, Schneider ML, Bister K, Hartl M*. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1). Oncogene20, 7524-7535 (2001).
  15. Hartl M*, Reiter F, Bader AG, Castellazzi M, Bister K. JAC, a direct target of oncogenic transcription factor Jun, is involved in cell transformation and tumorigenesis.  Natl. Acad. Sci. USA98, 13601-13606 (2001).
  16. Hartl M*, Bader AG, Bister K. Molecular targets of the oncogenic transcription factor Jun.  Cancer Drug Targets3, 41-57 (2003).
  17. Hartl M, Matt T, Schüler W, Siemeister G, Kontaxis G, Kloiber K, Konrat R, Bister K. Cell transformation by the v-myc oncogene abrogates c-Myc/Max-mediated suppression of a C/EBPbeta-dependent lipocalin gene.  Mol. Biol.333, 33-46 (2003).
  18. Hartl M*, Karagiannidis AI, Bister K. Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis. Oncogene25, 4043-4055 (2006).
  19. Reiter F, Hartl M, Karagiannidis AI, Bister K. WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential. Oncogene26, 1769-1779 (2007).
  20. Varela-Nieto I, Hartl M, Gorospe I, Leon Y. Anti-apoptotic actions of insulin-like growth factors: Lessons from development and implications in neoplastic cell transformation.  Pharm. Design13, 687-703 (2007).
  21. Schedlbauer A, Ozdowy P, Kontaxis G, Hartl M, Bister K, Konrat R. Backbone assignment of osteopontin, a cytokine and cell attachment protein implicated in tumorigenesis.  NMR Assign. 2, 29-31 (2008).
  22. Karagiannidis AI, Bader AG, Hartl M*, Bister K. TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motif. Virology378, 371–376 (2008).
  23. Hartl M*, Nist A, Khan MI, Valovka T, Bister K. Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1).  Natl. Acad. Sci. USA106, 5604-5609 (2009). 
  24. Hartl M, Mitterstiller A, Valovka T, Breuker K, Hobmayer B, Bister K. Stem cell-specific activation of an ancestral mycprotooncogene with conserved basic functions in the early metazoan Hydra Natl. Acad. Sci. USA 107, 4051-4056 (2010).
  25. Coudevylle N, Geist L, Hötzinger M, Hartl M, Kontaxis G, Bister K, Konrat R. The v‑myc-induced Q83 lipocalin is a siderocalin.  Biol. Chem.285, 41646-41652 (2010).
  26. Aigner M, Hartl M, Fauster K, Steger J, Bister K, Micura R. Chemical synthesis of site-specifically 2'-azido-modified RNA and potential applications for bioconjugation and RNA interference. ChemBioChem12, 47-51 (2011).
  27. Ganisl B, Valovka T, Hartl M, Taucher M, Bister K, Breuker K. Electron detachment dissociation for top-down mass spectrometry of acidic proteins.  Eur. J.17, 4460-4469 (2011).
  28. Shahnaz G, Hartl M, Barthelmes J, Leithner K, Sarti F, Hintzen F, Rahmat D, Salvenmoser W, Bernkop-Schnürch A. Uptake of phenothiazines by the harvested chylomicrons ex vivo model: influence of self-nanoemulsifying formulation design.  J. Pharm. Biopharm. 79, 171-180 (2011).
  29. Platzer G, Schedlbauer A, Chemelli A, Ozdowy P, Coudevylle N, Auer R, Kontaxis G, Hartl M, Miles AJ, Wallace BA, Glatter O, Bister K, Konrat R. The metastasis-associated extracellular matrix protein osteopontin displays transient structure formation in ligand interaction sites. Biochemistry 50, 6113-6124 (2011).
  30. Coudevylle N, Hoetzinger M, Geist L, Kontaxis G, Hartl M, Bister K, Konrat R. Lipocalin Q83 reveals a dual ligand binding mode with potential implications for the functions of siderocalins. Biochemistry 50, 9192-9199 (2011).
  31. Fauster K, Hartl M, Santner T, Aigner M, Kreutz C, Bister K, Ennifar E, Micura R. 2'‑Azido RNA – a versatile tool for chemical biology: Synthesis, X-ray structure, siRNA applications, and click labeling. ACS Chem. Biol. 7, 581-589 (2012).
  32. Hobmayer B, Jenewein M, Eder D, Eder MK, Glasauer S, Gufler S, Hartl M, Salvenmoser W. Stemness in Hydra– a current perspective.  J. Dev. Biol. 56, 509-517 (2012).
  33. Hartl M, Bister K. Oncogenes. In Brenner's Encyclopedia of Genetics, 2ndedition, Vol 5 (Maloy S, Hughes K, eds), pp. 164-166. Academic Press, San Diego (2013).
  34. Hartl M, Bister K. Analyzing Myc in cell transformation and evolution. In The Myc Gene: Methods and Protocols,Methods in Molecular Biology, Vol. 1012 (Soucek L, Sodir NM, eds), pp. 21-49. Humana Press, New York (2013).
  35. Valovka T, Schönfeld M, Raffeiner P, Breuker K, Dunzendorfer-Matt T, Hartl M, Bister K. Transcriptional control of DNA replication licensing by Myc.  Rep. 3: 3444 (2013). 
  36. Santner T, Hartl M, Bister K, Micura R. Efficient access to 3'-terminal azide-modified RNA for inverse click-labeling patterns. Bioconjugate Chem. 25, 188-195 (2014).
  37. Hartl M*, Glasauer S, Valovka T, Breuker K, Hobmayer B, Bister K. Hydra myc2, a unique pre-bilaterian member of the mycgene family, is activated in cell proliferation and gametogenesis.  Open 3, 397-407 (2014).
  38. Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, Rhee J-K, Baksh MM, Stefan E, Hartl M, Bister K, Vogt PK, Janda KD. Inhibitor of MYC identified in a Kröhnke pyridine library.  Natl. Acad. Sci. USA111, 12556-12561 (2014).
  39. Raffeiner P, Röck R, Schraffl A, Hartl M, Hart JR, Janda KD, Vogt PK, Stefan E, Bister K. In vivoquantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget 5, 8869-8878 (2014).
  40. Jud L, Kosutic M, Schwarz V, Hartl M, Kreutz C, Bister K, Micura R. Expanding the scope of 2'-SCF3 modified RNA.  Eur. J.21, 10400-10407 (2015).
  41. Ijaz M, Bonengel S, Zupančič O, Yaqoob M, Hartl M, Hussain S, Huck CW, Bernkop-Schnürch A. Development of oral self nano-emulsifying delivery system(s) of lanreotide with improved stability against presystemic thiol-disulfide exchange reactions. Expert Opin Drug Deliv. 13, 923-929 (2016).
  42. Hartl M*. The quest for targets executing MYC-dependent cell transformation. Front Oncol6: 132 (2016).
  43. Raffeiner P, Schraffl A, Schwarz T, Röck R, Ledolter K, Hartl M, Konrat R, Stefan E, Bister K. Calcium-dependent binding of Myc to calmodulin. Oncotarget8, 3327-3343 (2017).
  44. Gufler S, Artes B, Bielen H, Krainer I, Eder MK, Falschlunger J, Bollmann A,  Ostermann T, Valovka T, Hartl M, Bister K, Technau U, Hobmayer B. β-Catenin acts in a position-independent regeneration response in the simple eumetazoan Hydra.   Biol.433, 310-323 (2018).
  45. Lommel M, Strompen J, Hellewell AL, Balasubramanian GP, Christofidou ED, Thomson AR, Boyle AL, Woolfson DN, Puglisi K, Hartl M, Holstein TW, Adams JC, Özbek S. Hydra mesoglea proteome identifies thrombospondin as a conserved component active in head organizer restriction.  Rep.8: 11753 (2018).
  46. Hartl M*, Glasauer S, Gufler S, Raffeiner A, Puglisi K, Breuker K, Bister K, Hobmayer B. Differential regulation of mychomologs by Wnt/b-Catenin signaling in the early metazoan HydraFEBS J. 286, 2295-2310 (2019).
  47. Hartl M*, Schneider R.  A unique family of neuronal signaling proteins implicated in oncogenesis and tumor suppression.  Oncol. 9: 289 (2019).
  48. Hartl M*, Puglisi K, Nist A, Raffeiner P, Bister K. The brain acid-soluble protein 1 (BASP1) interferes with the oncogenic capacity of MYC and its binding to calmodulin. Mol Oncol. 14, 625-644 (2020).

*corresponding author

Nach oben scrollen